Amarin Corp Plc (AMRN)

[dukesking]

HK, Great post. I hope this is something payers will figure out and make the appropriate change to the language that caps the REDUCEIT indication to trigs <500. If they adhere to this language, it suggests that they could deny any script for Vascepa once your trigs drop below <150. That suggests that Vascepa is being treated as a lipid modulator not a CVD treatment. It also suggest that a patient that has severe CVD risk, and initial trigs <150, would be denied Vascepa. UHC decision is a huge step in the right direction but needs refining or at least language that allows the doctor to treat the patient not the trigs.